A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 30 Jan 2018 Status changed from recruiting to discontinued.
- 20 Jun 2016 New trial record